MCL1 inhibitor

DRUG CLASS:

MCL1 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
SS18-SSX fusion	Soft Tissue Sarcoma	SS18-SSX fusion	Soft Tissue Sarcoma	venetoclax + S63845 Sensitive: C3 – Early Trials venetoclax + S63845 Sensitive : C3	venetoclax + S63845 Sensitive: C3 – Early Trials venetoclax + S63845 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3	AZD5991 Sensitive: C3 – Early Trials AZD5991 Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	S63845 + S55746 Sensitive: D – Preclinical S63845 + S55746 Sensitive : D	S63845 + S55746 Sensitive: D – Preclinical S63845 + S55746 Sensitive : D
MCL1 expression	Multiple Myeloma	MCL1 expression	Multiple Myeloma	APG-3526 Sensitive: D – Preclinical APG-3526 Sensitive : D	APG-3526 Sensitive: D – Preclinical APG-3526 Sensitive : D
BCL2L11 deletion	Diffuse Large B Cell Lymphoma	BCL2L11 deletion	Diffuse Large B Cell Lymphoma	S63845 Resistant: D – Preclinical S63845 Resistant : D	S63845 Resistant: D – Preclinical S63845 Resistant : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D
MCL1 expression	Diffuse Large B Cell Lymphoma	MCL1 expression	Diffuse Large B Cell Lymphoma	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D	venetoclax + S63845 Sensitive: D – Preclinical venetoclax + S63845 Sensitive : D
MCL1 expression	Diffuse Large B Cell Lymphoma	MCL1 expression	Diffuse Large B Cell Lymphoma	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
BCL2 expression	Diffuse Large B Cell Lymphoma	BCL2 expression	Diffuse Large B Cell Lymphoma	S63845 Resistant: D – Preclinical S63845 Resistant : D	S63845 Resistant: D – Preclinical S63845 Resistant : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + AMG 176 Sensitive: D – Preclinical venetoclax + AMG 176 Sensitive : D	venetoclax + AMG 176 Sensitive: D – Preclinical venetoclax + AMG 176 Sensitive : D
MCL1 expression	Multiple Myeloma	MCL1 expression	Multiple Myeloma	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
BCL2 expression	Multiple Myeloma	BCL2 expression	Multiple Myeloma	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
BCL2 overexpression	Acute Myelogenous Leukemia	BCL2 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
BCL2L1 overexpression	Acute Myelogenous Leukemia	BCL2L1 overexpression	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D	venetoclax + AZD5991 Sensitive: D – Preclinical venetoclax + AZD5991 Sensitive : D
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	AZD5991 Resistant: D – Preclinical AZD5991 Resistant : D	AZD5991 Resistant: D – Preclinical AZD5991 Resistant : D
ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	ATM deletion + SF3B1 mutation	Chronic Lymphocytic Leukemia	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	BCL2 overexpression + MCL1 overexpression	Gastroesophageal Cancer	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D	AT 101 Sensitive: D – Preclinical AT 101 Sensitive : D
CD34 positive	Acute Myelogenous Leukemia	CD34 positive	Acute Myelogenous Leukemia	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D
CD34 positive + MN1 overexpression + MCL1 elevation	Acute Myelogenous Leukemia	CD34 positive + MN1 overexpression + MCL1 elevation	Acute Myelogenous Leukemia	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D	S63845 + BMIi-1 Sensitive: D – Preclinical S63845 + BMIi-1 Sensitive : D
STK11 deletion + KRAS mutation	Non Small Cell Lung Cancer	STK11 deletion + KRAS mutation	Non Small Cell Lung Cancer	AMG 176 + MEK inhibitor Sensitive: D – Preclinical AMG 176 + MEK inhibitor Sensitive : D	AMG 176 + MEK inhibitor Sensitive: D – Preclinical AMG 176 + MEK inhibitor Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + AMG 176 Sensitive: D – Preclinical gilteritinib + AMG 176 Sensitive : D	gilteritinib + AMG 176 Sensitive: D – Preclinical gilteritinib + AMG 176 Sensitive : D
MCL1 overexpression	Colorectal Cancer	MCL1 overexpression	Colorectal Cancer	APG1244 + MCL1 inhibitor Sensitive: D – Preclinical APG1244 + MCL1 inhibitor Sensitive : D	APG1244 + MCL1 inhibitor Sensitive: D – Preclinical APG1244 + MCL1 inhibitor Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	encorafenib + S63845 Sensitive: D – Preclinical encorafenib + S63845 Sensitive : D	encorafenib + S63845 Sensitive: D – Preclinical encorafenib + S63845 Sensitive : D
BST1 positive	Acute Myelogenous Leukemia	BST1 positive	Acute Myelogenous Leukemia	S63845 Sensitive: D – Preclinical S63845 Sensitive : D	S63845 Sensitive: D – Preclinical S63845 Sensitive : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	S63845 + A-1331852 Sensitive: D – Preclinical S63845 + A-1331852 Sensitive : D	S63845 + A-1331852 Sensitive: D – Preclinical S63845 + A-1331852 Sensitive : D
FBXW7 underexpression	Breast Cancer	FBXW7 underexpression	Breast Cancer	JQ-1 + S63845 Sensitive: D – Preclinical JQ-1 + S63845 Sensitive : D	JQ-1 + S63845 Sensitive: D – Preclinical JQ-1 + S63845 Sensitive : D
SMARCA4 deletion	Lung Cancer	SMARCA4 deletion	Lung Cancer	PRT1419 + PRT3789 Sensitive: D – Preclinical PRT1419 + PRT3789 Sensitive : D	PRT1419 + PRT3789 Sensitive: D – Preclinical PRT1419 + PRT3789 Sensitive : D

MCL1 inhibitor

MCL1 inhibitor

Associations(34)

Associations
(34)